Bemis Co. reports Tuesday that third-quarter net income fell 19% from a year ago, undercut by acquisition financing costs and lower unit volume sales of its packaging materials.

Among the shares expected to see active trade in Tuesday’s session are those of Visa, McKesson and TD Ameritrade.

The global pharmaceuticals market is expected to reach $967 billion by 2011 -- which is why companies are always looking for that next must-have drug. Staying profitable and pleasing shareholders means constant innovation but the FDA approval process for a new drug can take over a decade to complete and the cost can exceed $800 million. From there on average only 5 out of every 5 000 will make it to market. And there’s no guarantee any of those 5 will turn a profit. That’s why Big Pharma’s latest innovations aren’t new drugs -- they’re new syndromes and disorders. ...

NEW YORK (MarketWatch) -- July has been anything but a sleepy month in the corporate-bond market and investor willingness to wade into corporate bonds is likely to keep the window open for companies in coming months, analysts said.

These companies have consistently increased their payments for 25 years.

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by AnalystChoice.com (AC).

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by RothmanResearch.com.

Increases Full Year 2009 Guidance to $1.81 to $1.86 Per Share